Johnson & Johnson says Puerto Rico plants 'fared well' in Maria but 'intermittent' shortages possible

Johnson & Johnson reported that its Puerto Rico manufacturing is getting back up to speed after Hurricane Maria.

In the wake of the devastating Hurricane Maria in Puerto Rico, Johnson & Johnson executives say the company's manufacturing facilities "fared well" and are getting back up to full speed.

"Intermittent" drug shortages are possible, they said, but the company doesn't expect the storm to make a significant dent in its finances, executives told analysts and investors on Tuesday's third-quarter conference call. 

J&J has six manufacturing sites on the island and all are open in "varying stages of capacity," CFO Dominic Caruso said on Tuesday. The company has already started shipping new products from Puerto Rico manufacturing sites after the storm, he added. 

Hurricane Maria hit Puerto Rico late last month, leaving much of the island in wreckage and causing dozens of deaths. Even still, many residents are without power and water. 

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

After the storm, FDA Commissioner Scott Gottlieb traveled there to meet with pharmaceutical executives and assess the damage. At the time, the FDA had a list of more than three dozen drugs it feared could run scarce as a result of Hurricane Maria. Thirteen are made only in Puerto Rico. 

RELATED: Hurricane Maria shutters much of Puerto Rico's pharma manufacturing 

“These are critical medicines,” Gottlieb told USA Today at the time. “These are not drugs for which there are therapeutic substitutes.”

The global pharma industry has a large manufacturing footprint in Puerto Rico, representing 72% of the country's exports or $14.5 billion last year, according to the U.S. Bureau of Labor Statistics.  

RELATED: FDA concerned about possible drug shortages in wake of devastation in Puerto Rico 

All told, there are 50 pharma plants on the island. Immediately after the storm, most were operating on backup power and with limited employees as Puerto Rico residents worked to recover. Reports have said it could take several months to completely restore power on the island. 

AbbVie, Amgen, Eli Lilly, AstraZeneca and Bristol-Myers Squibb are among the other drugmakers with plants in Puerto Rico. 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.